Findings

What do systematic reviews say?

870 questions · 912 findings · 85 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 65 · 7.1%GRADE not reported 34 · 3.7%Very low 115 · 12.6%Low 273 · 29.9%Moderate 330 · 36.2%High 95 · 10.4%

Prostacyclin vs control

Headache+ · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 2351 participants
Moderate

Selexipag vs placebo

Improvement in WHO functional class · pulmonary arterial hypertension

Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 1.61 [0.17, 15.63]
1 study · 43 participants
Moderate

Selexipag vs placebo

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High

Selexipag vs placebo

All‐cause mortality · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
Moderate

Selexipag vs placebo

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Headache+ · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High

Prostacyclin vs control

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 2283 participants
Low

Prostacyclin vs control

All‐cause mortality · pulmonary arterial hypertension

Prostacyclin probably leads to lower mortality compared with control (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 0.6 [0.38, 0.94]
15 studies · 2554 participants
Moderate

Prostacyclin vs control

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1521 participants
Low

Prostacyclin vs control

Quality of life · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 271 participants
Moderate

Macrolide+tetracycline vs macrolides

Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 187 participants
Very low

Quinolone vs macrolides

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs tetracycline

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 0.44 [0.14, 1.38]
1 study · 50 participants
Low

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs tetracycline

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.52, 1.93]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found